Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 6/20 | 0.54 |
| ▸ | CA1 | P00915 | 6/20 | 0.54 |
| ▸ | CA9 | Q16790 | 6/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | AGER | Q15109 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5675273 | 0.76 | CA12 (0.46) | CA12CA1CA9CYP3A4CYP2A6 | |
| SCHEMBL6560676 | 0.75 | CA12 (0.60) | CA12CA1CA9CYP3A4CYP2A6 | |
| SCHEMBL11659593 | 0.75 | CA1 (0.52) | CA12CA1CA9CYP3A4CYP2A6 | |
| SCHEMBL4008731 | 0.71 | ABCG2 (0.60) | CA12CA1CA9CYP3A4HPGD | |
| SCHEMBL3328856 | 0.70 | MAOA (0.56) | CA12CA1CA9CYP3A4CYP2A6 | |
| SCHEMBL8515316 | 0.70 | CA12 (1.00) | CA12CA1CA9CYP3A4CYP2A6 | |
| SCHEMBL29393962 | 0.70 | CA12 (1.00) | CA12CA1CA9CYP3A4CYP2A6 | |
| SCHEMBL10518773 | 0.70 | CA12 (0.47) | CA12CA1CA9CYP3A4CYP2A6 | |
| SCHEMBL8512283 | 0.70 | CA12 (1.00) | CA12CA1CA9CYP3A4CYP2A6 | |
| SCHEMBL7128768 | 0.68 | HPGD (0.45) | CA12CA1CA9HPGDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9206201-B2 | Boronic acid bearing liphagane compounds as inhibitors of P13K-α and/or β | COUNSEL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2015-12-08 | — | — | US | disclosed |
| US-20150051173-A1 | BORONIC ACID BEARING LIPHAGANE COMPOUNDS AS INHIBITORS OF P13K- a AND/OR B | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2015-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150051173-A1 | BORONIC ACID BEARING LIPHAGANE COMPOUNDS AS INHIBITORS OF P13K- a AND/OR B | PIK3CA, PIK3C2A, PI4KA | CA12 3853/4885CA1 2305/4885CA9 958/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.